OTX-201 / BMS - LARVOL DELTA

OTX-201: A Novel Off-the-Shelf In Vivo Anti-CD19 CAR T Platform Designed to Improve Safety and Access to Immune Reset in Autoimmune Diseases (ACR Convergence 2026) - No abstract available

CAR T-Cell Therapy • Preclinical • Immunology

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics (Bristol-Myers Squibb Press Release) - "The acquisition includes Orbital’s lead RNA immunotherapy preclinical candidate currently in IND-enabling studies, OTX-201, which comprises an optimized circular RNA encoding a CD19-targeted CAR for in vivo expression delivered via targeted lipid nanoparticles (LNPs)....Additionally, BMS will acquire Orbital’s proprietary RNA platform, which integrates circular and linear RNA engineering, advanced LNP delivery, and AI-driven design to enable durable, programmable RNA therapies tailored to the distinct biology of a broad spectrum of diseases."

M&A • Immunology